Autifony Therapeutics Limited, a London, UK developer of novel pharmaceutical treatments for hearing disorders, closed an £8m extension to its Series A funding round.
Backers included SV Life Sciences, Imperial Innovations, Pfizer Venture Investments, the International Biotechnology Trust PLC (IBT), and UCL Business which had previously participated in the over £15m in Series A round.
The company intends to use the funds to carry out further clinical trials on its novel Kv3 ion
channel mechanism, which will include exploration of AUT00063 in a pilot study in patients with a cochlear
implant, and contribute to the clinical development of a second, differentiated Kv3 modulator, AUT00206, for the treatment of schizophrenia.
Formed in 2011 as a spin-out from GSK and led by Dr Charles Large, Chief Executive Officer, Autifony Therapeutics focuses on the development of novel medicines to treat hearing disorders and is now exploring the potential for its novel ion channel mechanism in other areas of high unmet medical need, such as tinnitus and schizophrenia.